In collaboration with research groups and the Hospital District of Helsinki and Uusimaa, we have set up drug sensitivity and resistance testing (DSRT) platform with a set of 461 approved and investigational oncology drugs on patient samples. Ex vivo drug testing is currently performed at FIMM with primary cancer cells from patients with leukemia and multiple myeloma as well as cancer cell lines. The drug sensitivity responses, measured by cell viability and death readouts, are integrated with molecular profiling such as exome sequencing, transcriptomics and phosphoproteomics. Application of the platform to AML patient samples has uncovered taxonomic drug-response subtypes and individualised therapy based on DSRT has resulted in several clinical responses. The DSRT platform enables drug repositioning, provides new combinatorial possibilities and allows for linking drug sensitivities to predictive biomarkers. We are developing the platform with additional readouts and increasing the number of drugs. Our Labcyte Access Workstation, with Echo550 and Echo525 integration, allows development and set-up of miniaturised follow-up assays, such as reverse-phase protein array and qPCR, using non-contact acoustic dispensing.
Drug Sensitivity and Resistance Testing Platform for Personalized Medicine at the Institute for Molecular Medicine Finland (FIMM)
Video Jun 23, 2015
Contrasting LBAs and LC-MS for Peptide and Protein BioanalysisVideo
Kelly Doering discusses ligand binding assays (LBAs) and compares the advantages and limitations of this technology to LC-MS.WATCH NOW
Garbage In = Garbage Out: Limited Peer Review in Cannabis SequencingVideo
Many companies are offering DNA sequencing for the cannabis field but not all of these companies have scientific staff that have published genomics papers. Do they know how to sequence? This recent review implies, in some cases, they do not.WATCH NOW